Please assess the completion status of the following clinical trial:

Trial Title: Fluoxetine for Visual Recovery After Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* MRI-confirmed acute ischemic stroke resulting in an isolated homonymous visual field loss.~Exclusion Criteria:~* Known hypersensitivity to fluoxetine or other selective serotonin reuptake inhibitors~* National Institutes of Health Stroke Scale score greater than 5~* Premorbid modified Rankin Scale score greater than 2~* Premorbid monocular or binocular visual field deficits~* Premorbid retinopathy or optic neuropathy~* Premorbid depression~* History of cognitive impairment, dementia, or neurodegenerative disorder~* History of seizure disorder~* History of mania or hypomania~* History of hyponatremia~* History of angle-closure glaucoma or elevated intraocular pressure~* Current alcohol abuse or impaired liver function~* Current use of an antidepressant medication~* Current use of a medication likely to have an adverse interaction with fluoxetine~* Current use of a medication likely to impair post-stroke recovery~* Contraindication to MRI~* Pregnancy or lactation~* Hemorrhagic transformation of the index stroke, resulting in mass effect~* Enrollment in another clinical trial at the time of the index stroke

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Fluoxetine (Type: EXPERIMENTAL): 20 mg fluoxetine capsule by mouth once daily for 90 days
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).